For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 6,819 | |||
| General and administrative | 5,158 | |||
| Total operating expenses | 11,977 | |||
| Loss from operations | -11,977 | |||
| Change in fair value of warrant liability | 0 | |||
| Interest income | 21 | |||
| Net loss | -11,956 | |||
| Deemed dividend on series b warrants | 0 | |||
| Net loss available to common stockholders | -11,956 | |||
| Basic EPS | -121.8 | |||
| Diluted EPS | -121.8 | |||
| Basic Average Shares | 98,162 | |||
| Diluted Average Shares | 98,162 | |||
GRI Bio, Inc. (GRI)
GRI Bio, Inc. (GRI)